newsfilter
← Latest News
PR Newswire·

Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome

-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants ---- Initial proof of concept data expected in second half of 2027 --SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc.